Comparative Pharmacology
Head-to-head clinical analysis: APRETUDE versus EMTRIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRETUDE versus EMTRIVA.
APRETUDE vs EMTRIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the integration of HIV-1 DNA into host genomic DNA, which is essential for viral replication. It binds to the active site of integrase and blocks the strand transfer step of retroviral DNA integration.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
600 mg IM every 2 months, initiated as two consecutive monthly loading doses of 600 mg each, for HIV-1 pre-exposure prophylaxis.
Emtricitabine 200 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours following subcutaneous injection, supporting monthly dosing.
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Renal (approximately 30% as unchanged drug) and fecal (approximately 50% as metabolites and unchanged drug) following oral administration.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Category C
Category C
Antiretroviral
Antiretroviral, NRTI